These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 23879247)

  • 21. Dermatologic adverse events to chemotherapeutic agents, Part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab.
    Choi JN
    Semin Cutan Med Surg; 2014 Mar; 33(1):40-8. PubMed ID: 25037257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.
    Lenz HJ
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):5-13. PubMed ID: 16736978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib.
    Beldner M; Jacobson M; Burges GE; Dewaay D; Maize JC; Chaudhary UB
    Oncologist; 2007 Oct; 12(10):1178-82. PubMed ID: 17962611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cutaneous toxicities of epidermal growth factor receptor inhibitors: A prospective study in 60 Asian patients.
    Chularojanamontri L; Tuchinda P; Likitwattananurak C; Pongparit K; Rujitharanawong C; Ithimakin S; Kulthanan K
    Asian Pac J Allergy Immunol; 2019 Mar; 37(1):12-18. PubMed ID: 29549700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Managing Cutaneous Side Effects From Targeted Molecular Inhibitors for Melanoma and Nonmelanoma Skin Cancer.
    Tang N; Ratner D
    Dermatol Surg; 2016 Jan; 42 Suppl 1():S40-8. PubMed ID: 26730973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.
    Guttman-Yassky E; Mita A; De Jonge M; Matthews L; McCarthy S; Iwata KK; Verweij J; Rowinsky EK; Krueger JG
    Eur J Cancer; 2010 Jul; 46(11):2010-9. PubMed ID: 20621734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.
    Yalici-Armagan B; Ayanoglu BT; Demirdag HG
    Cutan Ocul Toxicol; 2019 Sep; 38(3):261-266. PubMed ID: 31010330
    [No Abstract]   [Full Text] [Related]  

  • 28. The histologic spectrum of epithelial neoplasms induced by sorafenib.
    Kwon EJ; Kish LS; Jaworsky C
    J Am Acad Dermatol; 2009 Sep; 61(3):522-7. PubMed ID: 19700018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.
    Edmonds K; Hull D; Spencer-Shaw A; Koldenhof J; Chrysou M; Boers-Doets C; Molassiotis A
    Eur J Oncol Nurs; 2012 Apr; 16(2):172-84. PubMed ID: 21641280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.
    Lynch TJ; Kim ES; Eaby B; Garey J; West DP; Lacouture ME
    Oncologist; 2007 May; 12(5):610-21. PubMed ID: 17522250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical approaches to minimize rash associated with EGFR inhibitors.
    Oishi K
    Oncol Nurs Forum; 2008 Jan; 35(1):103-11. PubMed ID: 18192159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cutaneous reactions to novel therapeutics.
    Hoang MP; Kroshinsky D
    Am J Dermatopathol; 2012 Oct; 34(7):679-87; quiz 688-90. PubMed ID: 23000876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toward evidence-based management of the dermatologic effects of EGFR inhibitors.
    LoRusso P
    Oncology (Williston Park); 2009 Feb; 23(2):186-94. PubMed ID: 19323301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.
    Agero AL; Dusza SW; Benvenuto-Andrade C; Busam KJ; Myskowski P; Halpern AC
    J Am Acad Dermatol; 2006 Oct; 55(4):657-70. PubMed ID: 17010747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toxicity of targeted therapy in non-small-cell lung cancer management.
    Ricciardi S; Tomao S; de Marinis F
    Clin Lung Cancer; 2009 Jan; 10(1):28-35. PubMed ID: 19289369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Severe cutaneous reaction to cetuximab with possible association with the use of over-the-counter skin care products in a patient with oropharyngeal cancer.
    Waris W; Naik S; Idrees I; Taha H; Camosino L; Mehrishi A; Saif MW
    Cutan Ocul Toxicol; 2009; 28(1):41-4. PubMed ID: 19514925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in the management of cutaneous toxicities of targeted therapies.
    Robert C; Sibaud V; Mateus C; Cherpelis BS
    Semin Oncol; 2012 Apr; 39(2):227-40. PubMed ID: 22484194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
    Eames T; Landthaler M; Karrer S
    Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
    [No Abstract]   [Full Text] [Related]  

  • 39. EGFR-targeted therapy and related skin toxicity.
    Morse L; Calarese P
    Semin Oncol Nurs; 2006 Aug; 22(3):152-62. PubMed ID: 16893744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.